288 related articles for article (PubMed ID: 28268215)
1. Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Strang J; Reed K; Bogdanowicz K; Bell J; van der Waal R; Keen J; Beavan P; Baillie S; Knight A
Eur Addict Res; 2017; 23(2):61-70. PubMed ID: 28268215
[TBL] [Abstract][Full Text] [Related]
2. Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine
.
Strang J; Knight A; Baillie S; Reed K; Bogdanowicz K; Bell J
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):81-85. PubMed ID: 29231163
[TBL] [Abstract][Full Text] [Related]
3. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
6. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
[TBL] [Abstract][Full Text] [Related]
8. Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.
Hjelmström P; Banke Nordbeck E; Tiberg F
Drug Dev Ind Pharm; 2020 Jan; 46(1):1-7. PubMed ID: 31914818
[No Abstract] [Full Text] [Related]
9. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R
Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
11. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
12. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
[TBL] [Abstract][Full Text] [Related]
13. The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.
Guillery SPE; Reiners S; Fahrner M; Enge S; Hellweg R; Kunte H; Kronenberg G
Addict Biol; 2023 May; 28(5):e13275. PubMed ID: 37186443
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.
Greenwald MK; Comer SD; Fiellin DA
Drug Alcohol Depend; 2014 Nov; 144():1-11. PubMed ID: 25179217
[TBL] [Abstract][Full Text] [Related]
15. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
[TBL] [Abstract][Full Text] [Related]
16. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
Accurso AJ; Lee JD; McNeely J
J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
[TBL] [Abstract][Full Text] [Related]
20. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
